1. Home
  2. SAFE vs ARDX Comparison

SAFE vs ARDX Comparison

Compare SAFE & ARDX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo Safehold Inc. New

SAFE

Safehold Inc. New

HOLD

Current Price

$15.56

Market Cap

1.1B

Sector

Real Estate

ML Signal

HOLD

Logo Ardelyx Inc.

ARDX

Ardelyx Inc.

HOLD

Current Price

$5.66

Market Cap

1.3B

Sector

Health Care

ML Signal

HOLD

Company Overview

Basic Information
Metric
SAFE
ARDX
Founded
2016
2007
Country
United States
United States
Employees
N/A
N/A
Industry
Real Estate Investment Trusts
Biotechnology: Pharmaceutical Preparations
Sector
Real Estate
Health Care
Exchange
Nasdaq
Nasdaq
Market Cap
1.1B
1.3B
IPO Year
1999
2014

Fundamental Metrics

Financial Performance
Metric
SAFE
ARDX
Price
$15.56
$5.66
Analyst Decision
Hold
Strong Buy
Analyst Count
10
7
Target Price
$19.00
$15.14
AVG Volume (30 Days)
279.8K
2.8M
Earning Date
04-30-2026
04-30-2026
Dividend Yield
4.48%
N/A
EPS Growth
7.43
N/A
EPS
0.40
N/A
Revenue
$385,552,000.00
$2,607,000.00
Revenue This Year
N/A
$37.75
Revenue Next Year
$4.31
$34.24
P/E Ratio
$39.53
N/A
Revenue Growth
5.43
N/A
52 Week Low
$12.76
$3.54
52 Week High
$17.16
$8.40

Technical Indicators

Market Signals
Indicator
SAFE
ARDX
Relative Strength Index (RSI) 55.00 41.52
Support Level $15.23 $5.46
Resistance Level $15.81 $6.23
Average True Range (ATR) 0.40 0.25
MACD 0.09 -0.00
Stochastic Oscillator 56.57 32.69

Price Performance

Historical Comparison
SAFE
ARDX

About SAFE Safehold Inc. New

Safehold Inc is a REIT that operates its business by acquiring, managing, and capitalizing ground leases. Ground leases are long-term contracts between the landlord (the Company) and a tenant or leaseholder. Ground leases generally represent ownership of the land underlying commercial real estate projects that are net leased by the fee owner of the land to the owners/operators of the real estate projects built thereon.

About ARDX Ardelyx Inc.

Ardelyx Inc is a biopharmaceutical company developing and commercialize, first-in-class medicines that meet unmet medical needs. It has developed a platform that enabled the discovery of new biological mechanisms and pathways to develop potent and efficacious therapies that minimize the side effects and drug-drug interactions frequently encountered with traditional, systemically absorbed medicines. Its products Tenapanor, branded as IBSRELA, is used for the treatment of adults with IBS-C. Tenapanor, branded as XPHOZAH, is used to reduce serum phosphorus in adults with CKD on dialysis as add-on therapy in patients who have an inadequate response to phosphate binders or who are intolerant of any dose of phosphate binder therapy.

Share on Social Networks: